Leaky Gut & Intestinal Permeability
Peptides explored for leaky gut and intestinal permeability — BPC-157, KPV, larazotide, and GLP-2 / teduglutide. What the science actually says.
'Leaky gut' is a controversial term. In mainstream gastroenterology, the more precise framing is 'increased intestinal permeability' — a measurable disruption of the tight junctions between intestinal epithelial cells that allows larger-than-normal molecules to cross the gut barrier into the lamina propria and bloodstream. The phenomenon is real and well-characterized in inflammatory bowel disease, celiac disease, NSAID-induced enteropathy, certain infections, and some autoimmune conditions. The contested claim is whether 'leaky gut' is also a stand-alone driver of fatigue, brain fog, food sensitivities, autoimmunity, and the broad symptom complex that alternative-health communities attribute to it.
The peptides discussed for leaky gut sit at the intersection of these two views. BPC-157 has well-documented animal evidence for protecting and restoring intestinal mucosal integrity in models of induced damage. KPV (the C-terminal tripeptide of α-MSH) reduces intestinal inflammation through melanocortin receptor and NF-κB pathways. Larazotide acetate is a tight-junction-stabilizing octapeptide that reached Phase III clinical trials for celiac disease. GLP-2 and its long-acting analog teduglutide are intestinal trophic peptides — teduglutide is FDA-approved for short bowel syndrome.
This page covers what these peptides actually do, what they have been validated for in regulated trials, and how to think about their use in the broader 'leaky gut' conversation.
Peptides discussed for Leaky Gut & Intestinal Permeability
Larazotide
Tight Junction Regulator
A synthetic peptide that regulates intestinal tight junctions, in clinical trials for celiac disease and studied for leaky gut conditions.
Teduglutide
GLP-2 Analogue
An FDA-approved GLP-2 analogue that promotes intestinal growth, used for short bowel syndrome.
BPC-157
Gastric Peptide
A synthetic peptide derived from a protective protein found in gastric juice, widely discussed for tissue repair and recovery.
KPV
Anti-Inflammatory Tripeptide
A tripeptide fragment of alpha-MSH with potent anti-inflammatory properties, studied for inflammatory bowel disease and skin conditions.
How peptides target leaky gut & intestinal permeability
Four mechanisms make peptides relevant to intestinal permeability. First, BPC-157 — derived from a 15-amino-acid sequence within human gastric juice — has been shown across rodent studies to protect against and reverse mucosal injury from NSAIDs, alcohol, stress, and surgical insult. The mechanisms reported include nitric oxide system modulation, growth factor receptor upregulation at the injury site, and angiogenesis at the regenerating mucosa. Sikiric and colleagues have published extensively on BPC-157's gastrointestinal protective effects across multiple injury models, making this one of the most-studied indications for the peptide.
Second, KPV (lysine-proline-valine) is the anti-inflammatory active fragment of α-melanocyte-stimulating hormone. It signals through melanocortin receptors (primarily MC1R) and inhibits NF-κB-mediated inflammation. Animal models of colitis show that oral KPV (which survives gastric passage relatively well due to its small size and stability) reaches the colon in active form and reduces inflammatory damage at low doses. KPV is the basis for some prescription anti-inflammatory bowel formulations and is the focus of considerable investigational interest for IBD.
Third, larazotide acetate is an octapeptide that stabilizes tight junctions by antagonizing zonulin signaling. Zonulin is a regulator of intestinal tight junction integrity; in celiac disease and some other conditions, zonulin signaling is upregulated and tight junctions become abnormally permeable. Larazotide reached Phase III trials in celiac disease as an adjunct to gluten-free diet, with mixed primary endpoint results that did not produce a market-approved product but did establish proof-of-mechanism in humans.
Fourth, GLP-2 (glucagon-like peptide-2) is the intestinal-specific cousin of GLP-1. It stimulates intestinal villus growth, enterocyte proliferation, and mucosal mass. Teduglutide (a GLP-2 analog with extended half-life, marketed as Gattex/Revestive) is FDA-approved for parenteral-nutrition-dependent short bowel syndrome and is the only intestinal trophic peptide with regulatory approval.
What the evidence shows
The honest assessment varies by peptide. BPC-157 has extensive animal evidence for intestinal protection and repair across multiple injury models — NSAID-induced ulcers, alcohol-induced gastric damage, colitis models, anastomosis healing, post-surgical adhesion reduction. The mechanism work is consistent and the effect sizes are meaningful. Human evidence is anecdotal: there are no randomized controlled trials of BPC-157 for any GI indication in humans, despite decades of preclinical work. Clinical use is off-label and based on extrapolation from rodent data.
KPV has growing animal and early-human evidence for inflammatory bowel disease. Multiple murine colitis studies show oral KPV reduces inflammatory damage and tissue infiltrate. Translation to human IBD has progressed through investigator-initiated work and case-series reports, with formal Phase II/III trials in progress for some KPV-related compounds.
Larazotide is the only peptide on this page with Phase III human trial data for an intestinal-permeability-related indication (celiac disease). Trial results were mixed — some endpoints met, primary efficacy endpoints not consistently met — and the drug has not been FDA-approved despite multiple Phase III readouts. The mechanism is validated in humans even if the clinical effect was insufficient for approval at the doses and endpoints tested.
Teduglutide has been FDA-approved since 2012 for short bowel syndrome and represents the most-validated intestinal-repair peptide. It is not used for 'leaky gut' as a primary indication but is a real intestinal trophic peptide with controlled-trial evidence.
For the broader 'leaky gut as cause of fatigue / brain fog / autoimmunity' framing, no peptide has validated efficacy for that symptom complex because the framing itself remains contested in mainstream gastroenterology. People who use peptides for self-diagnosed leaky gut should be aware they are extrapolating well beyond the regulatory evidence base.
What to expect
Reported use patterns: oral BPC-157 (often as a 'BPC-157 Arginate' salt formulation marketed as more stable for oral delivery) at 250-500 mcg twice daily, typically for 4-6 weeks. Some users report subjective improvement in bloating, post-meal discomfort, and general GI tolerance over the course. Others report no change. KPV oral capsules at 500 mcg twice daily are used for inflammatory presentations.
For people with formally diagnosed celiac disease or IBD, peptides are adjuncts to a gastroenterologist-directed plan, not a substitute for the underlying treatment (gluten-free diet for celiac; mesalamine, immunomodulators, or biologics for IBD). For people with self-diagnosed leaky gut without endoscopic or laboratory confirmation, peptide protocols are speculative — there may be benefit, but there is no validated way to measure response or to confirm that the original problem was an intestinal permeability issue at all.
Diet and lifestyle factors generally have larger and better-validated effects on gut barrier function than peptide protocols: reducing chronic NSAID use, treating SIBO if present, stress management, and sleep optimization all have measurable effects on intestinal permeability markers in human studies.
Important caveats
'Leaky gut' as a stand-alone diagnosis is not generally accepted in mainstream gastroenterology — the related concept of increased intestinal permeability is well-characterized in specific disease states but is not currently considered a primary cause of broader systemic symptoms. People with persistent GI symptoms (bloating, pain, altered bowel habits, weight loss, blood in stool) should have a proper gastroenterology workup before assuming leaky gut. Celiac disease, inflammatory bowel disease, microscopic colitis, SIBO, and food intolerances all require specific diagnosis-driven treatment that peptides do not replace. Pregnant or breastfeeding people, anyone with active GI bleeding, and people with bowel obstruction should not start peptide protocols without medical supervision.
Frequently asked questions
Is leaky gut a real condition?
Increased intestinal permeability — the underlying biology — is real and well-characterized in inflammatory bowel disease, celiac disease, NSAID enteropathy, and some other conditions. 'Leaky gut syndrome' as a stand-alone driver of fatigue, brain fog, autoimmunity, and food sensitivities is more contested and is not a recognized diagnosis in mainstream gastroenterology. The peptide conversation about leaky gut sits across both views — some uses target validated mechanisms (e.g., larazotide for tight junction dysfunction), others extrapolate beyond the evidence base.
What is the best peptide for leaky gut?
If 'leaky gut' means tight-junction-permeability-driven disease, larazotide acetate is the most-studied peptide with Phase III human trial data, though it is not FDA-approved. If the underlying problem is mucosal damage (NSAID injury, post-surgical, IBD), BPC-157 has the strongest animal evidence for repair. For inflammatory presentations, KPV has growing human evidence. For diagnosed short bowel syndrome, teduglutide is FDA-approved. There is no single 'best' — the right peptide depends on the underlying problem.
Does BPC-157 heal leaky gut?
In rats, BPC-157 reverses experimental mucosal damage from NSAIDs, alcohol, stress, and other insults. The effect is consistent across many models. In humans, there are no randomized controlled trials of BPC-157 for any GI indication, despite decades of animal work. Use is extrapolative — the biology is plausible and clinical anecdotes are common, but the controlled trial that would establish efficacy has not been done. Anyone with significant GI symptoms should have a workup, not just a peptide protocol.
How long does it take peptides to heal leaky gut?
Animal models show measurable improvement in mucosal integrity over 1-2 weeks of consistent BPC-157 dosing. Human anecdotal reports describe symptom improvement over 4-6 weeks. Larazotide trials in celiac disease showed effects over 12+ weeks. Realistic expectations: weeks to months, not days. The slow timeline matches mucosal turnover biology — the small intestinal epithelium replaces itself every 4-7 days, but full mucosal architecture restoration takes longer.
Can you take BPC-157 orally for gut healing?
Native BPC-157 has limited oral bioavailability because of gastric and pancreatic protease degradation. The arginate salt form (BPC-157 Arginate) is marketed as a more orally stable variant, and oral capsules are widely used for GI indications on the rationale that local mucosal contact may produce effect even with low systemic absorption. Subcutaneous injection produces higher and more reliable systemic levels. For purely local gut effects, oral may be sufficient; for systemic effects, injection is the more-studied route.
Are peptides safer than steroids for gut inflammation?
For diagnosed inflammatory bowel disease (Crohn's, ulcerative colitis), corticosteroids and biologics have decades of randomized controlled evidence and clear regulatory status. Peptides do not replace them. For non-IBD inflammation or as adjuncts, peptides may offer a more favorable side-effect profile than chronic steroid use — but adjunct status, not replacement, is the right framing. Anyone considering reducing or stopping prescribed IBD medication should do so only with their gastroenterologist's guidance.
Part of these goals
Related conditions
Peptide families relevant to Leaky Gut & Intestinal Permeability
Antimicrobial Peptides
The peptide family of host-defense antimicrobial peptides — LL-37 (the human cathelicidin), KPV (the alpha-MSH-derived anti-inflammatory tripeptide), lactoferricin (the lactoferrin-derived antimicrobial), DS-5, plus the broader research-tier cluster including tuftsin, hepcidin, and larazotide. Antimicrobial peptides are an active drug-development area for resistant infections, mucosal immunity, and inflammatory disease, with origins traceable to Michael Zasloff's 1987 discovery of the magainins.
Melanocortins
The peptide family of α-MSH analogs and selective melanocortin-receptor agonists — covering pigmentation (afamelanotide, melanotan-II), monogenic obesity (setmelanotide), and female sexual desire (bremelanotide / PT-141), plus the immunomodulatory KPV tripeptide and the cosmetic α-MSH analog nonapeptide-1.
Stacks that overlap
- KLOW Peptide Stack (BPC-157 + TB-500 + GHK-Cu + KPV)
KLOW is a pre-mixed four-peptide compounded blend combining BPC-157 and TB-500 systemic repair, GHK-Cu collagen remodeling, and KPV anti-inflammatory coverage in a single 80 mg vial. It extends the popular GLOW formulation with an explicit anti-inflammatory layer.
Updated 2026-05-07